Almirall: FDA accepts expanded indication for acne drug

(CercleFinance.com) - US health regulators have accepted approval to Almirall's Aczone acne drug to include patients aged 9-11, the Spanish drugmaker said on Wednesday.


Aczone 7.5% gel is a prescription medicine used on the skin to treat inflammatory and non-inflammatory acne, previously approved in February 2016 for patients of 12 years and older.

While acne may be commonly thought of as an issue for teenagers, it also exists for children under the age of 12.

Copyright (c) 2019 CercleFinance.com. All rights reserved.